Aurobindo Pharma arm bags USFDA nod for cancer drug Pazopanib

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-12-05 11:39 GMT | Update On 2024-12-05 11:39 GMT

Pune Pharmacist Loses Rs 95 Lakh in Medical Store Deal

Hyderabad: Aurobindo Pharma Limited has announced that its wholly owned subsidiary company, EugiaPharma Specialities Limited, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, 200 mg, of Novartis Pharmaceuticals Corporation.

Pazopanib Tablets, 200 mg is indicated for the treatment of adults with Advanced Renal Cell Carcinoma(RCC), and Advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy.

The product is expected to be launched in Q4FY25.

The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA.

This is the 179 th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products.

Medical Dialogues team had earlier reported that Aurobindo Pharma, Dr Reddy's Laboratories, and Hetero Labs and 3 other pharmaceutical companies had signed memorandums of understanding (MoUs) with the Telangana government for setting up facilities in the Pharma City with an investment of over Rs 5,260 crore.

Read also: Aurobindo Pharma, Dr Reddy's Labs and 4 others partner with Telangana to set up facilities in Pharma City

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 29 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Read also: Aurobindo Pharma Partners with Global Pharma Major for Respiratory Product Development

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Aurobindo Pharma arm bags USFDA nod for cancer drug Pazopanib

Similar News

Delhi HC Refuses to Lift Ban on Medipol Pharma After Substandard Clarithromycin, Noscapine Supplied to Armed Forces

Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion

USFDA Reappoints Vinay Prasad to Top Medical and Scientific Role

B Pharmacy Graduate Held for Operating Unauthorized Clinic in Hyderabad

No Generics for AbbVie's Rinvoq Until 2037, Analysts See Multi-Billion Dollar Boost

Advent to Sell Zentiva to Private Equity GTCR in USD 4.8 Billion Deal, Closing Expected in 2026

Chennai Court Acquits 2 After Alleged Nitravet Haul Found to Be Paracetamol

USFDA warns pharma cos to remove misleading ads